Halozyme Therapeutics (HALO): Notes From Investor Meetings - Piper Jaffray

September 16, 2016 7:45 AM EDT
Get Alerts HALO Hot Sheet
Price: $9.60 --0%

Rating Summary:
    12 Buy, 0 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 6 | New: 4
Trade HALO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Halozyme Therapeutics (NASDAQ: HALO) after hosting a series of investor meetings. He raised his PT to $18 from $15 on additional risk-adjusted value from the ENHANZE franchise. The analyst has "enhanced conviction in the long-term value of ENHANZE products based on patent life which is specific to each new product formulation, as well as the clinical advantages of SC delivery to drive growth".

The analyst also thinks Stage 2 PFS results from PEGPH20 in pancreatic cancer during 4Q16 could pleasantly surprise investors given the better selected patient population and uninterrupted dosing schedule (vs Stage 1). He is also confident these results should support design of the enrolling Phase III and provide better guide posts for PoS calculus. PC has been a tough indication but he believes this HA-targeted approach may prove to be differentiated.

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $11.10 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Comments

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment